Evidence map›Paper›PMID 41496405›Full record

ArticleTranslational oncology2026

Integrated spatial and single-cell transcriptomics reveals RPL8 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma.

Jinna Tan, Junzhu Liang, Yaoyang Li, Jiaqian He, Hui Yin, Hemeng Wu, Yuzhen Luo, Mingfen Li, Fuli Long, Hongsheng Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jinna TanGuangxi University of Chinese Medicine, Nanning 530200, China; First Clinical Medical College, Guangxi University of Chinese Medicine, Nanning, 530022, China.
Junzhu LiangGuangxi University of Chinese Medicine, Nanning 530200, China.
Yaoyang LiGuangxi University of Chinese Medicine, Nanning 530200, China.
Jiaqian HeGuangxi University of Chinese Medicine, Nanning 530200, China; First Clinical Medical College, Guangxi University of Chinese Medicine, Nanning, 530022, China.
Hui YinGuangxi University of Chinese Medicine, Nanning 530200, China; First Clinical Medical College, Guangxi University of Chinese Medicine, Nanning, 530022, China.
Hemeng WuClinical Laboratory Department, The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, 530023, China.
Yuzhen LuoClinical Laboratory Department, The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, 530023, China.
Mingfen LiClinical Laboratory Department, The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, 530023, China.
Fuli LongDepartment of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China.
Hongsheng LinClinical Laboratory Department, The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, 530023, China. Electronic address: linhs@gxtcmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsRibosomal protein L8 (RPL8) is up-regulated in hepatocellular carcinoma (HCC), yet its clinical value and microenvironment role remain unclear.

methodsMulti-omics (TCGA, CPTAC), scRNA-seq (GSE146115) and spatial transcriptomics were integrated; function was tested by RPL8 knockdown, proliferation/migration assays and drug-sensitivity screens.

resultsRPL8 mRNA/protein were markedly elevated (p < 0.001) with AUC 0.95 for diagnosis. High RPL8 independently predicted shorter overall (HR 1.42) and disease-specific survival (HR 1.35). Mechanistically, RPL8 co-activated MYC/G2M signaling, rewired glutathione metabolism and correlated with cell-cycle/DNA-repair scores (p < 0.001). scRNA-seq showed selective RPL8 enrichment in malignant hepatocytes and exhausted CD8

conclusionsRPL8 drives HCC progression and immune evasion, qualifying it as a diagnostic biomarker and therapeutic target.

Indexed as

BiomarkerHepatocellular carcinomaIntegrated multi-omics analysisRPL8Single cell sequencingSpatial transcriptomics

Identifiers

PMID41496405
PMCPMC12813052

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.